Oxilia has a range of clinical advantages

X Icon with Square Background

Highly cost effective

Works across multiple solid tumours

Single injection prior to radiotherapy

Compatible with existing standard of care & current radiotherapy equipment

No change to existing patient pathways

Inert until activated by radiotherapy

Potential to enhance response to immunotherapy by triggering immunogenic cell death


Oxilia has a clear regulatory pathway

  • Classified as CLASS III medical device by UK MHRA (Innovation office engaged)
  • ISO 13485 compatible QMS implemented and externally audited
  • Pre-clinical programme fully costed and validated by MHRA
  • US regulatory consultancy (Covingtons) advise FDA will classify as medical device
  • Outline pilot clinical trial plan developed by Theradex with clinician feedback and reviewed by MHRA
X Icon